{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:43:21Z","timestamp":1787499801782,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Key Technologies R&D Program","award":["2015BAI13B09"],"award-info":[{"award-number":["2015BAI13B09"]}]},{"name":"Beijing Hospitals Authority Clinical Medicine Development","award":["XMLX202102"],"award-info":[{"award-number":["XMLX202102"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biliary tract cancer (BTC) is a highly malignant tumor, with limited therapy regimens and short response duration. In this study, we aim to assess the efficacy and safety of the combination of camrelizumab, apatinib, and capecitabine as the first- or second-line treatment in patients with advanced BTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase 2, nonrandomized, prospective study, eligible patients received camrelizumab (200 mg, d1, Q3W), apatinib (250 mg, qd, d1-d21, Q3W), and capecitabine (1000 mg\/m\u00b2, bid, d1-d14, Q3W) until trial discontinued. The primary endpoint was the objective response rate (ORR). The secondary endpoints were disease control rate, progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From July 2019 to April 2023, we enrolled a total of 28 patients, of whom 14 patients were in the first-line treatment setting and 14 patients were in the second-line setting. At the data cutoff (April 30, 2023), the median follow-up duration was 18.03 months. Eight of 28 patients reached objective response (ORR: 28.57%), with an ORR of 50% and 7.1% for first-line and second-line treatment patients (P\u2005=\u2005.033). The median PFS was 6.30 months and the median OS was 12.80 months. Grade 3 or 4 adverse events (AEs) occurred in 9 (32.14%) patients, including elevated transaminase, thrombocytopenia, etc. No serious treatment-related AEs or treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this trial, the combination of camrelizumab, apatinib, and capecitabine showed promising antitumor activity and manageable toxicity in patients with advanced BTC, especially in the first-line setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>NCT04720131.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae154","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T02:34:46Z","timestamp":1718159686000},"page":"e1565-e1574","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2146-3448","authenticated-orcid":false,"given":"Chao","family":"Jing","sequence":"first","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]},{"name":"National Clinical Research Center for Digestive Diseases , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuinan","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiegao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]},{"name":"National Clinical Research Center for Digestive Diseases , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]},{"name":"National Clinical Research Center for Digestive Diseases , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["People\u2019s Republic of China"]},{"name":"National Clinical Research Center for Digestive Diseases , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"issue":"10272","key":"2024110817120778200_CIT0001","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2024110817120778200_CIT0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2024110817120778200_CIT0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2024110817120778200_CIT0004","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1053\/j.gastro.2009.02.038","article-title":"Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas","volume":"136","author":"Everhart","year":"2009","journal-title":"Gastroenterology"},{"issue":"14","key":"2024110817120778200_CIT0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"2024110817120778200_CIT0006","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaoncol.2020.6166","article-title":"Efficacy of capecitabine plus irinotecan vs irinotecan monotherapy as second-line treatment in patients with advanced gallbladder cancer: a multicenter phase 2 randomized clinical trial (GB-SELECT)","volume":"7","author":"Ramaswamy","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"2024110817120778200_CIT0007","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/annonc\/mdz058","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"2024110817120778200_CIT0008","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024110817120778200_CIT0009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-020-00862-w","article-title":"Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy","volume":"13","author":"Pan","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2024110817120778200_CIT0010","doi-asserted-by":"crossref","first-page":"e001240","DOI":"10.1136\/jitc-2020-001240","article-title":"Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial","volume":"8","author":"Chen","year":"2020","journal-title":"J ImmunoTher Cancer"},{"issue":"8","key":"2024110817120778200_CIT0011","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"issue":"12","key":"2024110817120778200_CIT0012","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"17","key":"2024110817120778200_CIT0013","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2024110817120778200_CIT0014","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"2024110817120778200_CIT0015","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024110817120778200_CIT0016","doi-asserted-by":"crossref","first-page":"646979","DOI":"10.3389\/fonc.2021.646979","article-title":"The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"186","key":"2024110817120778200_CIT0017","first-page":"182","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study","volume":"7","author":"Villanueva","year":"2024","journal-title":"J Clin Oncol."},{"issue":"5","key":"2024110817120778200_CIT0018","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024110817120778200_CIT0019","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1093\/oncolo\/oyab073","article-title":"A phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma","volume":"27","author":"Monge","year":"2022","journal-title":"Oncologist"},{"issue":"6","key":"2024110817120778200_CIT0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"2024110817120778200_CIT0021","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2024110817120778200_CIT0022","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S2468-1253(22)00052-8","article-title":"First-line chemotherapy plus immunotherapy in biliary tract cancer","volume":"7","author":"Neuzillet","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"2024110817120778200_CIT0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"2024110817120778200_CIT0024","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"10391","key":"2024110817120778200_CIT0025","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"2024110817120778200_CIT0026","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024110817120778200_CIT0027","first-page":"S563","article-title":"52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-na\u00efve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"2024110817120778200_CIT0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.32548","article-title":"Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis","volume":"77","author":"Zhou","year":"2023","journal-title":"Hepatology"},{"key":"2024110817120778200_CIT0029","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","article-title":"Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review","volume":"10","author":"Gao","year":"2019","journal-title":"Front Pharmacol"},{"issue":"2","key":"2024110817120778200_CIT0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7150\/ijbs.89376","article-title":"Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers","volume":"20","author":"Miao","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"8","key":"2024110817120778200_CIT0031","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"2024110817120778200_CIT0032","doi-asserted-by":"crossref","first-page":"e2025109","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2024110817120778200_CIT0033","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"issue":"5","key":"2024110817120778200_CIT0034","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"2024110817120778200_CIT0035","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/cas.15299","article-title":"Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1-IL-8 signaling-mediated epithelial-mesenchymal transition in lung adenocarcinoma","volume":"113","author":"Yang","year":"2022","journal-title":"Cancer Sci"},{"issue":"3","key":"2024110817120778200_CIT0036","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","article-title":"Mutant IDH Inhibits IFNgamma-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1565\/60541950\/oyae154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1565\/60541950\/oyae154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T12:12:34Z","timestamp":1731067954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/11\/e1565\/7727660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,8,5]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae154","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,8,5]]}}}